S
Serenus Biotherapeutics
Privately held specialty biopharmaceutical company
About Serenus Biotherapeutics
Founded in 2014 by Dr. Menghis Bairu, Serenus Biotherapeutics, Inc. was a specialty biopharmaceutical company with a strategic focus on the African continent. The company was established to bridge the divide between the world's leading pharmaceutical markets and the growing demand for therapies in emerging African nations. Dr. Bairu, who served as CEO and President, brought extensive experience from a multi-decade career in the international biotechnology and pharmaceutical sectors, including roles at Genentech and Elan Corporation. His personal journey, from fleeing war-torn Eritrea to becoming a successful physician and biotech executive, fueled the company's mission to address unmet medical needs in underserved regions.
Serenus Biotherapeutics operated by in-licensing, registering, and commercializing late-stage drugs and medical devices that were already approved in markets like the United States, Europe, and Japan. The business model centered on securing commercialization rights for these products to treat diseases with high prevalence in Sub-Saharan Africa, such as hypertension and other chronic, non-communicable diseases. A key part of its strategy involved creating partnerships with global pharmaceutical companies to introduce their products to the African market. For instance, the company entered an agreement with Hanmi Pharmaceutical to supply 'Amosartan', a combination therapy for hypertension. This approach aimed to capitalize on the rising demand for advanced medications driven by economic growth and urbanization in Africa.
The company's financing was significantly bolstered in March 2015 when it secured an investment of up to $43 million from Malin Corporation plc, an Ireland-based global life sciences company. The deal involved an initial $18 million for a 41% stake, with provisions for Malin to increase its stake later. These funds were earmarked for operational development, building out a late-stage clinical development pipeline, and establishing a comprehensive supply chain network across its target markets. Despite its ambitions and securing significant venture capital, PitchBook data indicates the company ceased operations as of December 1, 2022.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Mar 2015 | $43M | $172M | Malin Corporation | — |
Growth signals
Latest recorded traffic for Serenus Biotherapeutics is 230 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Serenus Biotherapeutics in the San Francisco ecosystem
The Serenus Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Malin Corporation
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Serenus Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Serenus Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








